COMPOUND DEEP DIVES · RESEARCH PROTOCOLS & STACKS
Conventional wisdom places growth hormone secretagogues in a single undifferentiated category — compounds that push GH up, full stop. The preclinical mechanistic literature tells a more precise story. CJC-1295 No DAC (Modified GRF 1-29) and ipamorelin activate entirely separate receptor classes, trigger distinct intracellular signalling cascades, and when co-administered in research models, produce GH secretory responses that exceed what either compound generates alone. That supra-additive output isn’t incidental. It follows directly from dual-pathway architecture: one compound drives the GHRH-R → cAMP → PKA axis; the other drives GHS-R1a → phospholipase C → IP3 → intracellular calcium mobilisation. These pathways converge downstream but remain functionally independent at the receptor level — which is precisely why combining them in a structured research protocol is mechanistically coherent rather than merely additive.
What makes this stack worth understanding in depth is the pulsatility constraint. Pituitary somatotrophs don’t respond optimally to continuous GH-axis stimulation. Downstream STAT5b nuclear signalling — the primary transducer of anabolic GH signalling — is most efficiently activated by discrete GH bursts separated by low-GH troughs (Veldhuis et al., 2001, PMID: 11527085). CJC-1295 No DAC preserves that physiology. Unlike the DAC-conjugated version, which extends plasma half-life to days via albumin binding and effectively blurs pulsatility, the No DAC form carries a subcutaneous half-life estimated at approximately 30 minutes — long enough to reliably engage somatotrophs through a complete GHRH-R stimulation cycle, short enough to allow the trough required for pulse architecture. Paired with ipamorelin’s somatostatin-antagonising mechanism, the result is a dual-compound research model designed to interrogate both arms of endogenous GH axis regulation simultaneously. This post examines the receptor pharmacology, synergy mechanisms, and available outcome data that define this stack’s research rationale.
The experimental rationale for pairing a GHRH analog with a GHS-R1a agonist originates in the fundamental neurobiology of GH secretion. Pulsatile GH release from anterior pituitary somatotrophs is jointly controlled by two hypothalamic signals operating in opposition: GHRH drives GH release, while somatostatin tonically suppresses it. GH-releasing peptides — the class to which ipamorelin belongs — were identified as a third regulatory input acting primarily through GHS-R1a, a 7-transmembrane Gq-coupled receptor structurally and functionally distinct from the GHRH receptor (McKee et al., 1997, PMID: 9092793).
CJC-1295 No DAC is a synthetic analog of endogenous GRF 1-29 (the biologically active fragment of GHRH), modified at four amino acid positions — Ala²→Aib, stabilised residue at Leu⁸, and modifications at positions 15 and 27 — to confer resistance to dipeptidyl peptidase IV (DPP-IV) cleavage and oxidative degradation at Met²⁷. These substitutions extend plasma half-life from the ~2 minutes of native GRF 1-29 to an estimated ~30 minutes following subcutaneous administration. The GHRH-R itself is a Family B-III Gs-coupled GPCR whose activation by either endogenous GHRH or synthetic analogs drives adenylyl cyclase → cAMP → PKA → phosphorylation of L-type voltage-gated Ca²⁺ channels → GH granule exocytosis (Halmos et al., 2023, PMID: 37717982; Mayo et al., 2000, PMID: 11036940).
Ipamorelin (NNC 26-0161) is a selective pentapeptide GHS-R1a agonist. Its receptor — the GH secretagogue receptor — is expressed in both pituitary somatotrophs and hypothalamic arcuate neurons, and carries >90% sequence identity across rat, swine, and human species (McKee et al., 1997, PMID: 9092793). Critically, GHS-R1a maintains approximately 50% constitutive baseline activity, meaning ipamorelin acts as a full agonist superimposed on a tonically active system. The downstream cascade is mechanistically independent from GHRH-R: GHS-R1a signals through Gq → phospholipase C → IP3 + DAG → cytosolic Ca²⁺ mobilisation and PKC activation (Root et al., 2002, PMID: 12477295).
The synergy hypothesis has been tested most directly using GHRH + GHRP-2 or GHRP-6 combination protocols in human research models (Wideman et al., 2000, PMID: 11004017; Hanew et al., 1998, PMID: 9768668; Veldhuis et al., 2011, PMID: 21467302). Ipamorelin belongs to the same GHS-R1a agonist class as GHRP-2, though it carries a more selective receptor binding profile with reduced off-target ACTH/cortisol stimulation relative to GHRP-6 based on in vitro characterisation data.
CJC-1295 No DAC activates the GHRH-R on anterior pituitary somatotrophs. Ligand binding couples to Gs protein → adenylyl cyclase activation → intracellular cAMP accumulation → PKA activation → phosphorylation and opening of L-type voltage-gated Ca²⁺ channels → fusion of GH-containing secretory granules with the plasma membrane. The 2025 comprehensive review by Halmos et al. confirms that splice variant 1 (SV1) of the GHRH-R — which retains full cAMP signalling — is the dominant pituitary-expressed isoform, and that GHRH agonist analogs reliably recapitulate this full cascade (Halmos et al., 2025, PMID: 39934495).
Ipamorelin’s GHS-R1a pathway is orthogonal at the receptor and second-messenger level. GHS-R1a couples through Gq → phospholipase C → hydrolysis of PIP₂ → IP₃ (triggering endoplasmic reticulum Ca²⁺ release) and DAG (activating PKC) → cytosolic Ca²⁺ rise → parallel GH exocytosis. Because the Ca²⁺ source and the kinase effectors differ entirely from the GHRH-R cascade, simultaneous engagement of both receptors provides two independent GH release stimuli converging at the level of GH granule fusion machinery.
The downstream convergence point identified by Hanew et al. (1998, PMID: 9768668) is the arachidonic acid cascade — a shared third-messenger system that both PKA (from GHRH-R) and PKC (from GHS-R1a) can activate via phospholipase A₂. This explains why co-stimulation produces synergistic rather than merely additive GH release: both cascades feed into a common amplification node, while also stimulating GH exocytosis through their independent Ca²⁺ channels simultaneously.
The most important source of in vivo synergy between GHRH analogs and GHS-R1a agonists is not at the pituitary level — it’s hypothalamic. Ipamorelin, acting through GHS-R1a on hypothalamic neurons, antagonises central somatostatin tone. Somatostatin normally provides tonic inhibitory restraint on somatotrophs by coupling to inhibitory GPCRs that suppress adenylyl cyclase and block somatotroph depolarisation. When that restraint is reduced, GHRH-driven GH release — including the exogenous GHRH-R stimulation from CJC-1295 No DAC — proceeds against a lower inhibitory threshold, amplifying pulse amplitude (Wideman et al., 2000, PMID: 11004017; Root et al., 2002, PMID: 12477295).
Additionally, GHS-R1a agonism at the hypothalamic level stimulates endogenous GHRH release from arcuate nucleus GHRH neurons, compounding the somatotroph stimulation already provided by exogenous CJC-1295 No DAC. This dual hypothalamic action — reduced somatostatin AND increased endogenous GHRH release — is what transforms a potentially additive combination into a synergistic one in intact in vivo systems.
Veldhuis et al. (2001, PMID: 11527085) documented that discrete GH secretory bursts activate STAT5b nuclear signalling and drive muscle IGF-1 gene expression more effectively than equivalent GH delivered as a continuous basal exposure. This matters directly to protocol design: the ~30-minute subcutaneous half-life of CJC-1295 No DAC is specifically its research advantage over DAC-conjugated CJC-1295. The DAC moiety (Drug Affinity Complex) binds albumin, extending plasma half-life to days and converting the compound into an effectively continuous GHRH-R stimulator — blunting rather than amplifying the discrete GH pulse architecture.
The negative feedback loop that makes pulsatility essential is well-characterised. A 2025 mouse study using GHRH-specific GH receptor knockout (GHRH∆GHR) models demonstrated that eliminating GH receptor feedback specifically on arcuate GHRH neurons increased pulsatile GH amplitude, lean mass, and liver IGF-1 expression. Importantly, IGF-1 receptor signalling on GHRH neurons — not direct GH receptor feedback — was identified as the primary brake on GHRH output (Gusmao et al., 2025, PMID: 40172534). This confirms that the GH → liver → IGF-1 → GHRH neuron feedback axis is the dominant long-loop regulator, while GH receptor feedback at the GHRH neuron level plays a secondary short-loop role.
The most rigorous body composition outcome data for the GHS-R1a agonist class comes from Nass et al. (2008, PMID: 18981485): a 2-year double-blind RCT in 65 older adults (ages 60–81) using MK-677 (ibutamoren), an oral non-peptide GHS-R1a agonist at 25 mg/day. Fat-free mass increased by +1.1 kg versus −0.5 kg in the placebo group (P<0.001). GH and IGF-1 were restored toward young-adult ranges. Importantly, pulse frequency was unchanged while pulse amplitude increased — confirming that GHS-R1a agonism amplifies pulsatile physiology rather than replacing it. Cortisol increased by 47 nmol/L (P=0.020) and fasting blood glucose by approximately 0.3 mmol/L, which are class-effect signals warranting monitoring across GHS-R1a agonist research protocols.
For IGF-1 axis engagement specifically, Campbell et al. (2018, PMID: 28340044) demonstrated that MK-0677 produced a 1.76-fold increase in geometric mean IGF-1 versus 1.07-fold with placebo (P<0.001) — a 65% greater IGF-1 increase (95% CI: 33–104%) — in a 3-month randomised crossover study in 22 hemodialysis subjects. This confirms that GHS-R1a agonism robustly engages the IGF-1 axis even under significant metabolic burden.
In a ferret model of cisplatin-associated weight loss, ipamorelin specifically (1–3 mg/kg i.p.) inhibited weight loss by approximately 24% during the delayed phase (48–72 hours post-cisplatin), with a GHS-R1a agonist IC₅₀ of 11.7 µM for inhibiting ileal contractility — comparable to anamorelin’s 14.0 µM (Lu et al., 2024, PMID: 39043357). This positions ipamorelin’s anabolic mechanism at the receptor level rather than through secondary anti-emetic pathways.
Table 1: Mechanistic Profile — CJC-1295 No DAC vs. Ipamorelin
| Compound | Receptor Target | Intracellular Cascade | Hypothalamic Action | Estimated Subcutaneous t½ | Key Citation |
|---|---|---|---|---|---|
| CJC-1295 No DAC (Modified GRF 1-29) | GHRH-R (Gs-coupled) | cAMP → PKA → L-type Ca²⁺ channel → GH exocytosis | Directly stimulates GHRH-R on somatotrophs | ~30 min (DPP-IV resistant) | Halmos et al., 2023, PMID: 37717982 |
| Ipamorelin (NNC 26-0161) | GHS-R1a (Gq-coupled) | PLC → IP₃ + DAG → cytosolic Ca²⁺ + PKC → GH exocytosis | Antagonises somatostatin tone; stimulates endogenous GHRH release | ~2 h (estimated) | McKee et al., 1997, PMID: 9092793 |
Table 2: Key Outcome Data — GHS-R1a Agonist Class Research
| Study | Model | Compound | Dose / Duration | Key Outcome | Citation |
|---|---|---|---|---|---|
| Nass et al. (2008) | Human RCT (n=65, ages 60–81) | MK-677 (GHS-R1a agonist) | 25 mg/day oral, 24 months | FFM +1.1 kg vs −0.5 kg placebo (P<0.001); IGF-1 restored to young-adult range; cortisol +47 nmol/L | PMID: 18981485 |
| Campbell et al. (2018) | Human RCT crossover (n=22, hemodialysis) | MK-0677 (GHS-R1a agonist) | 25 mg/day oral, 3 months | IGF-1 increase 1.76-fold vs 1.07-fold placebo; 65% greater increase (P<0.001) | PMID: 28340044 |
| Lu et al. (2024) | Ferret model | Ipamorelin (GHS-R1a agonist) | 1–3 mg/kg i.p. | ~24% inhibition of delayed-phase weight loss; IC₅₀ 11.7 µM vs GHS-R1a | PMID: 39043357 |
| Wideman et al. (2000) | Human (n=18, men/women) | L-arginine + GHRP-2 | GHRP-2 1 µg/kg bolus | Supra-additive GH release with combined GHRH-pathway + GHS-R1a co-stimulation; exercise potentiated individual responses | PMID: 11004017 |
| Veldhuis et al. (2011) | Human crossover (n=25) | GHRH + GHRP-2 infusion | IV infusion model | Dual-peptide drive augmented both nadir and peak GH vs. either agent alone (P<0.001); peak responses greater in women (P=0.016) | PMID: 21467302 |
| Gusmao et al. (2025) | Mouse (GHRH∆GHR knockout) | GH receptor ablation on GHRH neurons | Genetic model | Increased GH pulse amplitude, lean mass, liver IGF-1; IGF-1R identified as dominant feedback brake | PMID: 40172534 |
Following GH secretory bursts — whether endogenous or secretagogue-amplified — GH acts on peripheral tissues through JAK2–STAT5b phosphorylation. In hepatocytes, STAT5b activation drives IGF-1 gene transcription and secretion into circulation. In skeletal muscle and bone, locally produced and circulating IGF-1 activates IGF-1R → PI3K → Akt → mTOR → protein synthesis. In adipose tissue, GH directly activates hormone-sensitive lipase (HSL) → increased free fatty acid mobilisation from visceral fat stores, preferentially shifting substrate utilisation away from glucose oxidation (Thorner et al., 1997, PMID: 9238854).
The Recomp Stack — pairing CJC-1295 with Tesamorelin and MOTS-c — addresses the GH axis alongside mitochondrial biogenesis. Researchers exploring the GH axis more broadly may also compare the Recomp Stack as a structured multi-compound research model through the Research Compound Catalogue.
The mechanistic case for CJC-1295 No DAC and ipamorelin co-stimulation is well-supported at the receptor pharmacology and intracellular signalling levels. The translational evidence base, however, carries several limitations that any rigorous reading of this literature must acknowledge.
Limitation 1: No published RCTs for this specific compound combination. There are no indexed peer-reviewed randomised or controlled trials directly evaluating CJC-1295 No DAC (Modified GRF 1-29) combined with ipamorelin as a co-administration protocol. All synergy data comes from GHRH + GHRP-class combination studies, primarily using GHRP-2 or GHRP-6 — not ipamorelin specifically. The structural and receptor-binding similarities between ipamorelin and GHRP-2/GHRP-6 provide a reasonable basis for mechanistic extrapolation, but direct extrapolation carries real uncertainty. The synergy observed with GHRP-2 in Wideman et al. (2000, PMID: 11004017) and Veldhuis et al. (2011, PMID: 21467302) cannot be assumed to replicate quantitatively with ipamorelin without dedicated study.
Limitation 2: CJC-1295 No DAC pharmacokinetics are inferred, not directly measured. The compound has no standalone published human pharmacokinetic trials indexed in PubMed. The estimated subcutaneous half-life of ~30 minutes is derived from comparison with modified GRF 1-29 analog literature, not direct measurement in pharmacokinetic studies. The exact bioavailability, Cmax timing, and receptor occupancy duration following subcutaneous bolus administration in the context of a co-administration protocol are uncharacterised in peer-reviewed literature.
Limitation 3: Ipamorelin-specific human data is extremely sparse. Ipamorelin appears in indexed literature primarily as a receptor pharmacology tool for characterising GHS-R1a. There are no published RCTs evaluating ipamorelin in isolation for GH, IGF-1, body composition, or safety endpoints in human research models. The most relevant body composition data (Nass et al., 2008, PMID: 18981485) used MK-677, an oral non-peptide GHS-R1a agonist with substantially different pharmacokinetics and bioavailability compared to injectable peptide ipamorelin. The +1.1 kg fat-free mass finding cannot be attributed to ipamorelin.
Limitation 4: Metabolic and HPA-axis off-target signals are class effects requiring monitoring. Nass et al. (2008) documented cortisol elevation of +47 nmol/L and fasting blood glucose increase of approximately 0.3 mmol/L with GHS-R1a agonism. Ipamorelin is characterised as more selective than GHRP-6 for ACTH/cortisol sparing based on in vitro receptor selectivity data, but this comparative selectivity advantage has not been confirmed in rigorous parallel-arm human studies. GHS-R1a baseline constitutive activity at approximately 50% of maximum means that appetite stimulation is a predictable class effect, not an idiosyncratic ipamorelin finding.
Limitation 5: IV infusion synergy data does not map directly to subcutaneous bolus pharmacokinetics. The Veldhuis et al. (2011) and Wideman et al. (2000) synergy studies used intravenous infusion models achieving precise and simultaneous receptor co-stimulation. Subcutaneous bolus co-administration of CJC-1295 No DAC and ipamorelin produces sequential absorption kinetics — the timing, peak overlap, and area-under-curve relationship of the two compounds when co-injected subcutaneously is uncharacterised in peer-reviewed literature. Whether the peak plasma concentrations of both compounds align to produce simultaneous somatotroph co-stimulation in the subcutaneous bolus model is an unresolved pharmacokinetic question.
Limitation 6: Study population generalisability. The most relevant human GHS-R1a agonist trials enrolled older adults (ages 60–81 in Nass et al.) and renally impaired hemodialysis subjects (Campbell et al., 2018). GH axis response magnitude in younger, healthy research populations with intact basal GH pulsatility may differ substantially. GH secretagogue effects on an already-functional somatotroph system have not been well-characterised in young-adult models.
Limitation 7: Pulsatile superiority data derives from exogenous GH studies. The evidence that pulsatile GH more effectively drives STAT5b signalling and muscle IGF-1 gene expression compared to continuous GH exposure comes from exogenous recombinant GH administration studies, not from secretagogue-stimulated endogenous GH pulses. Whether secretagogue-driven GH pulses replicate the discrete peak-and-trough profile of endogenous physiology at an amplitude and duration sufficient for optimal STAT5b activation is not directly established.
For researchers also exploring peptide compounds in tissue repair contexts, BPC-157 and TB-500 are documented separately in the Recovery Compounds section. The Wolverine Stack pairs BPC-157 and TB-500 for research protocols examining connective tissue and repair mechanisms distinct from the GH axis. Researchers interested in longevity-adjacent signalling may also find GHK-Cu and the Longevity Stack relevant as comparative reference points, since GH-axis modulation intersects with collagen synthesis and extracellular matrix remodelling pathways in preclinical models.
The CJC-1295 No DAC and ipamorelin research stack is mechanistically coherent in a way that most compound pairings are not. The two compounds engage genuinely independent receptor systems — GHRH-R via the cAMP-PKA axis, GHS-R1a via the PLC-IP₃-Ca²⁺ axis — with convergent downstream amplification through the arachidonic acid cascade and a functionally distinct hypothalamic synergy mechanism: ipamorelin’s GHS-R1a agonism reduces somatostatin tone and augments endogenous GHRH release simultaneously, compounding the somatotroph stimulation from exogenous CJC-1295 No DAC. The supra-additive GH response documented in GHRH + GHRP-class human combination studies provides the closest available proxy for what this dual-pathway architecture produces in intact systems.
The evidence base, however, is not complete. There are no published RCTs for this specific peptide pair. CJC-1295 No DAC pharmacokinetics are inferred rather than directly measured. Ipamorelin-specific human outcome data is essentially absent from indexed literature. Researchers approaching this protocol should engage with it as a mechanistically grounded hypothesis — one supported by receptor pharmacology, second-messenger characterisation, and class-level GHS-R1a agonist data — not as an established outcome-proven protocol.
For research teams examining the GH secretagogue axis in detail, the Research Notes section contains additional mechanistic context, and the full Research Compound Catalogue lists available compounds. The Recomp Stack and the Metabolic Compounds category provide structured multi-compound research contexts for protocols examining body composition endpoints alongside GH axis modulation.
Gusmao DO et al. (2025). GH-Releasing Hormone Neurons Regulate the Hypothalamic-Pituitary-Somatotropic Axis via Short-Loop Negative Feedback. Endocrinology. PMID: 40172534
Halmos G et al. (2025). Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Reviews in Endocrine & Metabolic Disorders. PMID: 39934495
Halmos G et al. (2023). Signaling mechanism of growth hormone-releasing hormone receptor. Vitamins and Hormones. PMID: 37717982
Lu Z et al. (2024). The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets. Physiology & Behavior. PMID: 39043357
Nass R et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of Internal Medicine. PMID: 18981485
Campbell GA et al. (2018). Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study. Nephrology, Dialysis, Transplantation. PMID: 28340044
Veldhuis JD et al. (2011). Complex regulation of GH autofeedback under dual-peptide drive: studies under a pharmacological GH and sex steroid clamp. American Journal of Physiology — Endocrinology and Metabolism. PMID: 21467302
Wideman L et al. (2000). Synergy of L-arginine and GHRP-2 stimulation of growth hormone in men and women: modulation by exercise. American Journal of Physiology — Regulatory, Integrative and Comparative Physiology. PMID: 11004017
Hanew K et al. (1998). Secretory mechanisms of GH-releasing peptide-, GH-releasing hormone-, and TRH-induced GH release in acromegaly. Journal of Clinical Endocrinology & Metabolism. PMID: 9768668
Veldhuis JD et al. (2001). Neurophysiological regulation and target-tissue impact of the pulsatile mode of growth hormone secretion in the human. Growth Hormone & IGF Research. PMID: 11527085
Root AW et al. (2002). Clinical pharmacology of human growth hormone and its secretagogues. Current Drug Targets — Immune, Endocrine and Metabolic Disorders. PMID: 12477295
Thorner MO et al. (1997). Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging. Recent Progress in Hormone Research. PMID: 9238854
Mayo KE et al. (2000). Regulation of the pituitary somatotroph cell by GHRH and its receptor. Recent Progress in Hormone Research. PMID: 11036940
McKee KK et al. (1997). Molecular analysis of rat pituitary and hypothalamic growth hormone secretagogue receptors. Molecular Endocrinology. PMID: 9092793
All compounds sourced through biohacker.team undergo third-party HPLC purity verification with certificates of analysis (COAs) available on request. Our research team maintains sourcing transparency as a non-negotiable standard — purity data is reviewed before any compound enters the catalogue, and batch-level testing is conducted to confirm identity and concentration. Researchers can review our sourcing and testing framework at biohacker.team/about/.
For research use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease or condition. All compounds are sold strictly for in-vitro and animal research purposes. Not approved for human use.